Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Bioadaptives (BDPT) Debt to Equity (2019 - 2025)

Bioadaptives' Debt to Equity history spans 7 years, with the latest figure at -$0.66 for Q3 2025.

  • For Q3 2025, Debt to Equity fell 15.9% year-over-year to -$0.66; the TTM value through Sep 2025 reached -$0.66, down 15.9%, while the annual FY2024 figure was -$0.72, 21.15% down from the prior year.
  • Debt to Equity for Q3 2025 was -$0.66 at Bioadaptives, up from -$0.7 in the prior quarter.
  • Across five years, Debt to Equity topped out at -$0.47 in Q4 2022 and bottomed at -$0.72 in Q4 2024.
  • The 5-year median for Debt to Equity is -$0.59 (2021), against an average of -$0.59.
  • The largest annual shift saw Debt to Equity plummeted 25371.99% in 2021 before it grew 25.85% in 2022.
  • A 5-year view of Debt to Equity shows it stood at -$0.51 in 2021, then increased by 7.15% to -$0.47 in 2022, then decreased by 25.5% to -$0.59 in 2023, then dropped by 21.15% to -$0.72 in 2024, then grew by 8.23% to -$0.66 in 2025.
  • Per Business Quant, the three most recent readings for BDPT's Debt to Equity are -$0.66 (Q3 2025), -$0.7 (Q2 2025), and -$0.63 (Q1 2025).